Home » Stocks » PPBT

Purple Biotech Ltd. (PPBT)

Stock Price: $4.61 USD -0.04 (-0.86%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $4.64 +0.03 (0.65%) Jan 22, 7:55 PM
Market Cap 78.47M
Revenue (ttm) 1,000,000
Net Income (ttm) -5.89M
Shares Out 1.94M
EPS (ttm) -3.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $4.61
Previous Close $4.65
Change ($) -0.04
Change (%) -0.86%
Day's Open 4.70
Day's Range 4.54 - 4.70
Day's Volume 241,297
52-Week Range 0.23 - 4.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 4 days ago

REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor imm...

Other stocks mentioned: KTOV
GlobeNewsWire - 2 weeks ago

Virtual Bell-Ringing Ceremony in Celebration of Company's Recent Name Change to Purple Biotech

GlobeNewsWire - 1 month ago

New Name Reflects Company's Evolution to Advancing First-in-Class Oncology Therapies

GlobeNewsWire - 2 months ago

TEL AVIV, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasio...

GlobeNewsWire - 2 months ago

The new cohort will explore the combination of CM24, Opdivo (“nivolumab”) and Abraxane (“albumin-bound paclitaxel; nab-paclitaxel”) in patients with pancreatic cancer The new cohort will explo...

GlobeNewsWire - 2 months ago

Patent covers NT219's combinations with multiple 2nd and 3rd generation EGFR inhibitors, including osimertinib (TAGRISSO®)

GlobeNewsWire - 3 months ago

Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance

GlobeNewsWire - 4 months ago

Top Line Results from First Part of the Study Expected in Second Half of 2021 Top Line Results from First Part of the Study Expected in Second Half of 2021

GlobeNewsWire - 4 months ago

Kitov’s patent coverage for CM24 and NT219 now extends to the U.S., EU, China, and multiple ROW countries

GlobeNewsWire - 5 months ago

TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...

GlobeNewsWire - 5 months ago

TEL AVIV, Israel, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...

Zacks Investment Research - 5 months ago

Is (KTOV) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 6 months ago

Company Evaluating NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for the Treatment of Recurrent and/or Metastatic Solid Tumors and Head and Neck Cancer

GlobeNewsWire - 6 months ago

Patent coverage for CM24 now extends to the U.S. and the EU

Seeking Alpha - 6 months ago

Ties With Merck Could Explain Kitov's Market Interest

GlobeNewsWire - 6 months ago

TEL AVIV, July 02, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr...

GlobeNewsWire - 6 months ago

TEL-AVIV, Israel, June 25, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...

GlobeNewsWire - 6 months ago

TEL-AVIV, Israel, June 23, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...

GlobeNewsWire - 8 months ago

Company to Evaluate NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer in ...

GlobeNewsWire - 8 months ago

TEL AVIV, Israel, May 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...

GlobeNewsWire - 8 months ago

Company Expects to Initiate Phase 1/2 Trial of NT-219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors ...

GlobeNewsWire - 8 months ago

Company Expects to Initiate Phase 1/2 Clinical trial, in Collaboration with Bristol Myers Squibb, with CM-24 in Combination with nivolumab (Opdivo®) in Second Half of 2020

Seeking Alpha - 8 months ago

Tufin Software Technologies Ltd. (TUFN) CEO Ruvi Kitov on Q1 2020 Results - Earnings Call Transcript

Other stocks mentioned: KTOV, TUFN
GlobeNewsWire - 8 months ago

TEL-AVIV, Israel, May 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasi...

GlobeNewsWire - 9 months ago

TEL-AVIV, Israel, April 20, 2020 (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune ev...

GlobeNewsWire - 10 months ago

TEL AVIV, Israel, March 12, 2020 (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune ev...

GlobeNewsWire - 10 months ago

Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced it will expan...

Seeking Alpha - 11 months ago

Tufin Software Technologies' (TUFN) CEO Ruvi Kitov on Q4 2019 Results - Earnings Call Transcript

Other stocks mentioned: KTOV, TUFN
GlobeNewsWire - 11 months ago

Patent Provides Coverage Until 2035 and Strengthens Company’s IP Portfolio

GlobeNewsWire - 11 months ago

TEL AVIV, Israel, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...

GlobeNewsWire - 1 year ago

TEL AVIV, Israel, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...

GlobeNewsWire - 1 year ago

TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune eva...

GlobeNewsWire - 1 year ago

TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...

Seeking Alpha - 1 year ago

Kitov Pharma recently updated their Consensi commercial agreement with Coeptis Pharmaceuticals. I review the original and updated agreement and provide my thoughts on the amendments.

GlobeNewsWire - 1 year ago

TEL AVIV, Israel, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...

GlobeNewsWire - 1 year ago

TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) --   Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune e...

Seeking Alpha - 1 year ago

Kitov Pharma presented encouraging NT-219 data that confirmed its mechanism of action in reversing drug resistance in mouse models. The company is planning on submitting an IND before year-end.

GlobeNewsWire - 1 year ago

Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, presented newly released proo...

Seeking Alpha - 1 year ago

Tufin Software Technologies Ltd. (TUFN) CEO Ruvi Kitov on Q2 2019 Results - Earnings Call Transcript

Other stocks mentioned: KTOV, TUFN
GlobeNewsWire - 1 year ago

TEL AVIV, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune eva...

GlobeNewsWire - 1 year ago

TEL AVIV, Israel, Aug. 29, 2019 (GLOBE NEWSWIRE) --   Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune e...

Seeking Alpha - 1 year ago

Kitov Pharma's Consensi is close to launching and will mark the company's transition into a commercial-stage company. However, the stock trades under $1 and is at risk for delisting.

Seeking Alpha - 1 year ago

Kitov is in the final stages of acquiring FameWave and their promising oncology agent CM-24. This acquisition now makes a Kitov an oncology-focused company.

About PPBT

Purple Biotech, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatme... [Read more...]

Industry
Biotechnology
Founded
2010
CEO
Itzhak Israel
Employees
9
Stock Exchange
NASDAQ
Ticker Symbol
PPBT
Full Company Profile

Financial Performance

In 2019, Purple Biotech's revenue was $1,000,000, a change of 0.00% compared to the previous year's $1,000,000. Losses were -$5.89 million, 5.82% more than in 2018.

Financial Statements